CD274 and small cell lung carcinoma: In IMpower133 and CASPIAN study, it has been confirmed that anti-programmed cell death ligand-1 (PD-L1) antibody atezolizumab or durvalumab combined with platinum-etoposide chemotherapy significantly prolonged both PFS and OS and reduced the risk of disease progression and death without significantly increasing the incidence of AEs as first-line treatment of ES-SCLC [5,6].